Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Teva, with nine buys and one hold among 10 covering firms. The average 12-month price target is $42, while several brokerages recently raised their targets to between $40 and $45.
• Teva shares opened at $36.04, near their 52-week high of $37.35, with a market capitalization of approximately $42 billion. The company reported quarterly revenue of $4.14 billion and EPS of $0.02, while analysts expect full-year EPS of $1.96.
• Insiders have been net sellers, with executives selling 259,831 shares worth about $9.1 million over the past 90 days. Institutional investors own 54.05% of the stock, and the company carries a debt-to-equity ratio of 1.56.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $42.00.

TEVA has been the topic of several recent analyst reports. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an "overweight" rating in a research note on Tuesday, July 28th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a report on Wednesday, May 6th. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, July 31st. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 30th.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the firm's stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the transaction, the executive vice president directly owned 172,184 shares in the company, valued at $6,131,472.24. This trade represents a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 259,831 shares of company stock worth $9,091,659 in the last ninety days. Company insiders own 0.54% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC boosted its position in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after buying an additional 755 shares during the period. Allworth Financial LP grew its stake in shares of Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after acquiring an additional 329 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock worth $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Global Retirement Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after acquiring an additional 292 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $36.04 on Tuesday. The company's 50-day moving average is $33.28 and its two-hundred day moving average is $32.86. Teva Pharmaceutical Industries has a 1-year low of $16.26 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.56, a current ratio of 0.88 and a quick ratio of 0.67. The firm has a market capitalization of $42.00 billion, a price-to-earnings ratio of 60.07, a PEG ratio of 3.78 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The business had revenue of $4.14 billion during the quarter. Analysts forecast that Teva Pharmaceutical Industries will post 1.96 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source